CytomX Therapeutics, Inc. (CTMX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Viewpoint - CytomX is focused on advancing its unique Probody therapeutic platform in oncology, aiming to enhance the therapeutic window of treatments [2][3]. Company Overview - CytomX is a South San Francisco-based biotech company specializing in oncology, with over 15 years of experience in developing and optimizing its Probody therapeutic platform [3]. Pipeline Development - The company is committed to building a highly differentiated pipeline, with expectations for continued progress in 2026 following a successful 2025 [2].